 Bacillus thuringiensis toxins active against scarab pests |
| We claim: 1. An isolated polynucleotid encoding a toxin which is active against scarab pests, said ... |
|
| Growth differentiation factor-8 transgenic mice |
| The present invention provides a cell growth and differentiation factor, GDF-8, a polynucleotide ... |
|
| Modulation of cholesteryl ester transfer protein (CETP) activity |
| The invention claimed is: 1. A method for treating or preventing atherosclerosis in a human or ... |
|
| Nucleic acids, vectors and host cells encoding heregulin |
| In accordance with the objects of this invention, we have identified and isolated novel ligand ... |
|
| Immunoreactive peptides from Epstein-Barr virus |
| What is claimed is: 1. A polypeptide consisting of an amino acid sequence having the formula: (.phi.... |
|
| DNA encoding stationary phase, stress response sigma factor from Mycobacterium tuberculosis |
| OF THE INVENTION It is a discovery of the present invention that entry of M. tuberculosis into a ... |
|
| Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| The present invention provides, among other things, a method of removing virus from a sample. The ... |
|
| .alpha.-.beta. C4BP-type recombinant heteromultimeric proteins |
| The object of the present invention is therefore to develop recombinant soluble heteromultimeric ... |
|
| Semi-refined carrageenan |
| The present invention provides methods for preparing a carrageenan product comprising the steps of ... |
|
|
HIV immunoassays using gag polypeptides
| Details |
Inventors: Luciw, Paul A.; Dina, Dino; Steimer, Kathelyn; Pescador, Ray Sanchez; George-Nascimento, Carlos; Parkes, Deborah; Hallewell, Rob; Barr, Philip J.; Truett, Martha;
Assignee: Chiron Corporation (Emeryville, CA)
Primary Examiner: Zeman; Mary K.
Assistant Examiner:
Attorney, Agent or Firm: Hoscheit; Dale H., Harbin; Alisa A., Blackburn; Robert P.
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides. |
|
DETAILED DESCRIPTION Nucleotide sequences and expression of nucleotide sequences are provided for detecting the presence of complementary sequences associated with a retroviral etiologic agent (HIV, e.
g.
, HIV-1 or -2) for lymphadenopathy syndrome (LAS), acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC), and for producing polypeptides.
The single-stranded sequences are at least 20, more usually of at least about 50 nucleotides in length, and may find use as probes.
The double-stranded sequences may find use as genes coding for expression of polypeptides, either fragments or complete polypeptides expressed by the virus or fused proteins, for use in diagnosis of HIV infection or evaluating stage of infection, the production of antibodies to HIV, and the production of vaccines.
Based on the nucleotide sequences, synthetic peptides may also be prepared.
Specific aspects of the invention include: 1.
A DNA construct comprising a replication system recognized by a unicellular microorganism and a DNA sequence coding for at least 20 bp of a human immunodeficiency virus (HIV) genome, said replication system being a non-HIV replication system; 2.
A DNA construct comprising a replication system recognized by a unicellular microorganism and a DNA sequence of at least about 21 bp having an open reading frame and having a sequence substantially complementary to a sequence found in the gag, env, or pol region of an HIV, coding for a polypeptide which is immunologically non-cross-reactive with HTLV-I and HTVL-II, and reactive with an HIV; 3.
A restriction endonuclease fragment of at least about 1.
5 kbp derived from restriction enzyme digestion by at least one restriction endonuclease of a DNA sequence coding for an HIV of the class HIV-1; 4.
A DNA sequence comprising a fragment of at least about 20 bp, wherein the strands are complementary to a restriction endonuclease fragment described in 3 above, said sequence duplexing with an HIV nucleic acid sequence and not duplexing with HTLV-I or HTLV-II under comparable selective hybridization conditions; 5
|
|
Drugs 
